September 2009 Volume 5 Number 9
Visit Nature Reviews Nephrology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=49&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Nephrology online. To purchase a subscription,
please visit:
http://links.ealert.nature.com/ctt?kn=40&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=72&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
*********************************************************************
Nature Reviews Nephrology Impact Factor: 5.594*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
ISN Nexus Symposium: The Kidney and the Vascular System: Emerging Culprits
in Pathogenesis and Advances in Therapy.
April 15-18, 2010; Kyoto (Japan)
http://links.ealert.nature.com/ctt?kn=92&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
YOUR SCIENCE CAREER: WHAT NEXT?
Explore your options at The Source Event: London 25/09/2009 and Berlin
04/12/09. Throughout the day conference sessions and workshops will
tackle a range of science career issues. Running alongside this is a
FREE career fair where you can meet employers who are actively looking
to recruit scientists.
Register now at:
http://links.ealert.nature.com/ctt?kn=42&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
AKI: fluid overload and mortality
Robert W. Schrier
p485 | doi:10.1038/nrneph.2009.138
http://links.ealert.nature.com/ctt?kn=37&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Sepsis: Should steroids be used to treat sepsis and septic shock?
p487 | doi:10.1038/nrneph.2009.115
http://links.ealert.nature.com/ctt?kn=5&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Transplantation: Half of older patients awaiting donor kidneys 'die before
transplantation'
p488 | doi:10.1038/nrneph.2009.118
http://links.ealert.nature.com/ctt?kn=2&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Transplantation: Kidneys from old donors: tackling the organ shortage
p488 | doi:10.1038/nrneph.2009.119
http://links.ealert.nature.com/ctt?kn=20&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Dialysis: Central venous catheter locks: heparin versus citrate
p489 | doi:10.1038/nrneph.2009.116
http://links.ealert.nature.com/ctt?kn=15&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
IN BRIEF
Genetics | Genetics | Genetics
p489 | doi:10.1038/nrneph.2009.122
http://links.ealert.nature.com/ctt?kn=81&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
IN BRIEF
Hypertension | Vascular disease | Hypertension | Transplantation
p490 | doi:10.1038/nrneph.2009.123
http://links.ealert.nature.com/ctt?kn=83&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Transplantation: ABCB1 genotype influences ciclosporin toxicity
p490 | doi:10.1038/nrneph.2009.117
http://links.ealert.nature.com/ctt?kn=16&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Transplantation: ABO-incompatible renal transplants: time for increased use?
Stanley C. Jordan
p491 | doi:10.1038/nrneph.2009.131
Use of ABO-incompatible renal transplants from living donors has proven
a viable and practical transplantation strategy. The protocols devised
through the Johns Hopkins Incompatible Kidney Transplant Program could
result in the most rapid escalation of access to organs in the modern
era of transplantation.
http://links.ealert.nature.com/ctt?kn=10&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Glomerular disease: Lupus nephritis treatment: are we beyond
cyclophosphamide?
Brad H. Rovin
p492 | doi:10.1038/nrneph.2009.130
Although ALMS, the largest prospective, randomized, controlled study
comparing mycophenolate mofetil to intravenous cyclophosphamide for
the initial treatment of severe lupus nephritis, failed to achieve its
primary end point of mycophenolate superiority, mycophenolate plus
corticosteroids has become the accepted standard of care. Are we really
beyond cyclophosphamide for severe lupus nephritis?
http://links.ealert.nature.com/ctt?kn=56&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
End-stage renal disease: GFR and albuminuria as predictors: two is better
than one
Enyu Imai
p494 | doi:10.1038/nrneph.2009.128
Identifying patients at risk of end-stage renal disease relying only on
measurement of both glomerular filtration rate and albuminuria could
greatly decrease the number of patients flagged for renal surveillance
without increasing the risk of overlooking high-risk individuals.
http://links.ealert.nature.com/ctt?kn=50&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Transplantation: Pregnancy after kidney donation: more questions than
answers
Michelle A. Josephson
p495 | doi:10.1038/nrneph.2009.129
Two recent reports in the American Journal of Transplantation focus on
the maternal and fetal outcomes of pregnancies in kidney donors and
provide tantalizing, if somewhat worrisome, observations. The findings
also leave us with several important unanswered questions.
http://links.ealert.nature.com/ctt?kn=54&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Dialysis: The sweetness of glitazones: randomized trials needed
Carmine Zoccali
p497 | doi:10.1038/nrneph.2009.127
Two observational studies report opposite effects of glitazones on
clinical outcomes in patients with ESRD. Given the limited reliability
of such studies in the assessment of moderate effects of treatment,
however, findings in these articles should prompt the generation of
hypotheses rather than dictate changes in clinical practice.
http://links.ealert.nature.com/ctt?kn=46&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Pharmacology: Defining the optimal dose of a new drug: a crucial decision
Hiddo Lambers Heerspink and Dick de Zeeuw
p498 | doi:10.1038/nrneph.2009.111
Defining the dose of a new renoprotective drug with the optimal
benefit-to-risk ratio is an important consideration for drug developers
and physicians. Have we learned from past experiences?
http://links.ealert.nature.com/ctt?kn=48&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Heparin-induced thrombocytopenia: a renal perspective
Samaha Syed and Robert F. Reilly
Published online: 28 July 2009
p501 | doi:10.1038/nrneph.2009.125
Heparin-induced thrombocytopenia (HIT) is a clinicopathologic syndrome
in which one or more clinical events, usually thrombocytopenia or
thrombosis, are temporally related to heparin administration and caused
by HIT antibodies. This Review examines HIT from a renal perspective,
discussing manifestations of HIT in patients on renal replacement therapy,
the recent association of HIT with increased mortality in hemodialysis
patients, newer aspects of HIT treatment in the renal patient, and
heparin rechallenge in individuals who revert to antibody-negative status.
Abstract: http://links.ealert.nature.com/ctt?kn=91&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=60&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
The pathogenesis and treatment of chronic allograft nephropathy
Can Li and Chul Woo Yang
Published online: 28 July 2009
p513 | doi:10.1038/nrneph.2009.113
The term 'chronic allograft nephropathy' describes a clinical syndrome
of proteinuria, hypertension and declining renal function, that is a
major cause of late graft loss in renal transplant recipients. In this
concise Review, authors from Korea discuss the contribution of immunological
and non-immunological factors to the pathogenesis of chronic allograft
nephropathy. In the absence of a definitive treatment protocol for the
condition, they offer recommendations to minimize some of these underlying
risk factors.
Abstract: http://links.ealert.nature.com/ctt?kn=89&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=63&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Impact of treating the metabolic syndrome on chronic kidney disease
Varun Agrawal, Aashish Shah, Casey Rice, Barry A. Franklin and
Peter A. McCullough
Published online: 28 July 2009
p520 | doi:10.1038/nrneph.2009.114
No large randomized, placebo-controlled trials have investigated whether
the metabolic syndrome affects hard renal outcomes. In this Review,
Varun Agrawal and colleagues evaluate the evidence of an association
between the metabolic syndrome and chronic kidney disease and examine
whether treatment of the syndrome improves renal outcomes. The authors
conclude their discussion detailing the challenges of defining the
metabolic syndrome and of selecting appropriate renal outcomes.
Abstract: http://links.ealert.nature.com/ctt?kn=87&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=66&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Inherited cerebrorenal syndromes
Scott J. Schurman and Steven J. Scheinman
p529 | doi:10.1038/nrneph.2009.124
In this Review, Schurman and Scheinman detail the clinical and genetic
features of syndromes with a defined genetic basis that are characterized
by the concomitant presence of abnormalities of the central nervous system
and kidneys. The authors focus their attention on the oculocerebrorenal
syndrome of Lowe and on ciliopathies-particularly Joubert syndrome and
Bardet-Biedl syndrome.
Abstract: http://links.ealert.nature.com/ctt?kn=14&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=80&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
Sodium thiosulfate in the treatment of calcific uremic arteriolopathy
Georg Schlieper, Vincent Brandenburg, Markus Ketteler and Jurgen Floege
p539 | doi:10.1038/nrneph.2009.99
Calcific uremic arteriolopathy (CUA), a condition associated with high
mortality, is most common among patients on dialysis. In this opinion
article, Georg Schlieper and his colleagues discuss the evidence on the
efficacy of administering sodium thiosulfate in the treatment of CUA.
Given the lack of large clinical trials, the authors also evaluate the
consultation of internet-accessible CUA case registries as a strategy to
inform the treatment of this disease and to design future studies.
Abstract: http://links.ealert.nature.com/ctt?kn=17&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=84&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Find this Table of Contents e-alert useful?
Sign up for the monthly alert from Nature Reviews Endocrinology and keep
up-to-date with the latest developments in the field of endocrinology.
Ensure you never miss a crucial article:
http://links.ealert.nature.com/ctt?kn=43&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
2008 impact factor: 6.702*
*2009 Journal Citation Reports (Thomson Reuters, 2009) Nature Reviews
Endocrinology was previously published as Nature Clinical Practice
Endocrinology & Metabolism
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=71&m=33901946&r=MTc2NDE4ODIzOQS2&b=2&j=NTcwNTcxNTES1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
